Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Human hepatitis B virus (HBV) is the prototype of a family of small DNA viruses that
productively infect hepatocytes, the major cell of the liver, and replicate by reverse …

Hepatitis B virus (HBV) infects more than 300 million people worldwide and is a common
cause of liver disease and liver cancer. HBV, a member of the Hepadnaviridae family, is a …

Hepadnaviruses (hepatitis B viruses) cause transient and chronic infections of the liver.
Transient infections run a course of several months, and chronic infections are often lifelong …

More effective and less resistance-prone antiviral agents are now available to treat hepatitis
B virus (HBV) infection. Profound, durable, therapeutic HBV DNA suppression to slow and …

Hepatitis B virus persistence in infected hepatocytes is due to the presence of covalently
closed circular DNA (cccDNA), the template for the transcription of viral RNAs. Antiviral …

Since the early 1990s, nanotechnology has led to new horizons in nanomedicine, which
encompasses all spheres of science including chemistry, material science, biology, and …

Aptamers are short single-stranded DNA or RNA oligonucleotides and can be selected from
synthetic combinatorial libraries in vitro. They have a high binding affinity and specificity for …

It is estimated conservatively that more than one third of the world's population has been
infected with the hepatitis B virus (HBV) and that there are 350 million people with chronic …

The host-virus interactions that determine the outcome of viral infections have fascinated me
ever since medical school. My first opportunity to actively pursue this interest came when I …